Back to Search
Start Over
Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
- Source :
- International Medical Case Reports Journal. 13:89-93
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- Background Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment. Case presentation We herein report the case of a 74-year-old woman who received crizotinib for metastatic ALK-positive NSCLC. During the crizotinib treatment, complex renal cystic lesions with invasion of perirenal spaces and iliopsoas muscle appeared; two complex hepatic cysts were also observed. Almost all lesions disappeared after switching to alectinib, a second-generation ALK inhibitor. Conclusion It would seem that alectinib is able to reduce in size and number hepatic and renal cysts caused by the crizotinib treatment. Nevertheless, further studies are needed to clarify the role of both crizotinib in the onset of renal and hepatic cysts and alectinib in their disappearance.
- Subjects :
- Alectinib
Crizotinib
business.industry
medicine.drug_class
General Medicine
030204 cardiovascular system & hematology
Tyrosine-kinase inhibitor
ALK inhibitor
03 medical and health sciences
0302 clinical medicine
Renal cysts
hemic and lymphatic diseases
030221 ophthalmology & optometry
Cancer research
Anaplastic lymphoma kinase
Medicine
Non small cell
Hepatic Cyst
business
medicine.drug
Subjects
Details
- ISSN :
- 1179142X
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- International Medical Case Reports Journal
- Accession number :
- edsair.doi...........6af23967aed3f2a09858e7c970e157ed